UNSPSC 51112704: Nedaplatin

This classification denotes a platinum compound with the molecular structure C2H2O3.PT.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8UQ3W6JXAN chemically known as cis-diammine(glycolato-o(sup 1),o(sup 2))platinum, but more commonly known as nedaplatin, which bears US NIH Compound Identifier 72120. European Medicines Agency schedules Nedaplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09178MIG.

The term NEDAPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34). bears NCI CUID C61099 and UMLS ID C0093999. Most nations, for tariff and trade purposes, schedule nedaplatin under HS 28439000 and SITC 52432. SMILES: C(C(=O)[O-])[O-].N.N.[Pt+2].

UNSPSC 51112704 Nedaplatin is a Commodity code covering a single pharmaceutical product, and state and local procurement activity under it appears minimal. The Texas Health and Human Services Commission issued a Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The RFI solicits vendor experience with direct contracting for self-insured employers and health plans in both private and government sectors, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. This is a preliminary information-gathering mechanism rather than a formal competitive solicitation, designed to inform the state's future procurement strategy before issuing a formal RFP.

The recent activity identified is limited to a single issuing body—the Texas Health and Human Services Commission—with no evidence of concurrent opportunities in other states or jurisdictions. The RFI does not specify award values, budget ranges, set-aside designations, or formal evaluation criteria, indicating the state remains in the exploratory phase of program design. No response data from vendors or subsequent solicitation notices are present in the source material, limiting visibility into whether this exploratory phase will transition to formal competitive procurement or what vendor interest materialized.